Secular trends associated with Enterobacteriaceae with a cefepime susceptible-dose-dependent MIC

Affiliations

¹ Henry Ford Hospital, Detroit, Michigan, USA Wayne State University, Detroit, Michigan, USA.
² Henry Ford Hospital, Detroit, Michigan, USA.
³ Henry Ford Hospital, Detroit, Michigan, USA Wayne State University, Detroit, Michigan, USA sldavis@wayne.edu.

Jamie L Wagner et al. Antimicrob Agents Chemother. 2015 Mar.

. 2015 Mar;59(3):1822-3.

doi: 10.1128/AAC.04491-14. Epub 2014 Dec 15.

¹ Henry Ford Hospital, Detroit, Michigan, USA Wayne State University, Detroit, Michigan, USA.
² Henry Ford Hospital, Detroit, Michigan, USA.
³ Henry Ford Hospital, Detroit, Michigan, USA Wayne State University, Detroit, Michigan, USA sldavis@wayne.edu.

No abstract available

Figures

1. Sagent Pharmaceuticals. 2013. Cefepime package insert. Sagent Pharmaceuticals, Schaumburg, IL.
1. Alves MD, Ribeiro VB, Tessari JP, Mattiello F, De Bacco G, Luz DI, Vieira FJ, Behle TF, Pasqualotto AC, Zavascki AP. 2014. Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study. J Antimicrob Chemother 69:1681–1687. doi:10.1093/jac/dku001. - DOI - PubMed
1. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–12. doi:10.1086/516284. - DOI - PubMed
1. Clinical and Laboratory Standards Institute. 2013. Cefepime breakpoint change for Enterobacteriaceae and introduction of the susceptible-dose dependent (SDD) interpretive category [press release]. community.clsi.org/micro/wp-content/uploads/sites/15/2013/07/Cefepime-BP... Accessed 28 Mar 2014.
1. Clinical and Laboratory Standards Institute. 2014. Analysis and presentation of cumulative antimicrobial susceptibility test data; approved guideline—4th ed. CLSI document M39-A4 Clinical and Laboratory Standards Institute, Wayne, PA.